Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 15 2021 - 6:17AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
Annual Report 2020 on Form 20-F
In accordance with Section 203.01 of the New York Stock Exchange
Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that
on 12 March 2021 it filed with the Securities and Exchange
Commission an Annual Report on Form 20-F that included audited
financial statements for the year ended 31 December 2020. GSK's
2020 Annual Report on Form 20-F is available online at GSK's
website at www.gsk.com/corporatereporting and
also online at www.sec.gov.
Ordinary Shareholders may also elect to receive notification by
email of the publication of financial reports by registering
on www.shareview.co.uk.
A hard copy version of the GSK 2020 Annual Report, together with
the Notice of Annual General Meeting will be available on or about
30 March 2021.
Shareholders have the ability to receive, upon request, a hard copy
version of GSK's complete audited financial statements for the year
ended 31 December 2020, free of charge, by either:
(i)
writing to Equiniti
Limited, our registrars in the UK, at the following address:
Equiniti Limited, Aspect House, Spencer Road, Lancing, West
Sussex BN99 6DA, or by telephone on 0371 384 2991 (inside the UK)
or +44 (0)121 415 7067 (outside the UK);
(ii)
writing to J.P. Morgan Chase Bank, N.A. our ADR
depositary in the US, at the following address: EQ Shareowner
Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by telephone
on +1 800 990 1135 (US toll free) or +1 651 453 2128 (outside the
US); or
(iii)
contacting the GSK Response Center in the USA at +1 888 825 5249
(US toll free).
Victoria Whyte
Company
Secretary
12
March 2021
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors" in the company's Annual Report on Form 20-F for
2020.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: March
15, 2021
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2024 to Oct 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2023 to Oct 2024